These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 39148544)
1. Association between PCSK9 inhibitors and acute kidney injury: a pharmacovigilance study. Liu H Front Pharmacol; 2024; 15():1353848. PubMed ID: 39148544 [TBL] [Abstract][Full Text] [Related]
2. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database. Welch HK; Kellum JA; Kane-Gill SL Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524 [TBL] [Abstract][Full Text] [Related]
4. Real-world safety of PCSK9 inhibitors: A pharmacovigilance study based on spontaneous reports in FAERS. Feng Z; Li X; Tong WK; He Q; Zhu X; Xiang X; Tang Z Front Pharmacol; 2022; 13():894685. PubMed ID: 36506552 [No Abstract] [Full Text] [Related]
5. Adverse event profiles of PCSK9 inhibitors alirocumab and evolocumab: Data mining of the FDA adverse event reporting system. Ji C; Bai J; Zhou J; Zou Y; Yu M Br J Clin Pharmacol; 2022 Dec; 88(12):5317-5325. PubMed ID: 35818959 [TBL] [Abstract][Full Text] [Related]
6. Musculoskeletal Adverse Events Associated with PCSK9 Inhibitors: Disproportionality Analysis of the FDA Adverse Event Reporting System. Ding L; Chen C; Yang Y; Fang J; Cao L; Liu Y Cardiovasc Ther; 2022; 2022():9866486. PubMed ID: 35140810 [TBL] [Abstract][Full Text] [Related]
7. Assessment of acute kidney injury related to small-molecule protein kinase inhibitors using the FDA adverse event reporting system. Fan Q; Ma J; Zhang B; Li Q; Liu F; Zhao B Cancer Chemother Pharmacol; 2020 Nov; 86(5):655-662. PubMed ID: 33001273 [TBL] [Abstract][Full Text] [Related]
9. Acute kidney injury associated with immune checkpoint inhibitors: A pharmacovigilance study. Zhu J; Wu J; Chen P; You K; Su J; Gao Z; Bi Z; Feng M Int Immunopharmacol; 2022 Dec; 113(Pt A):109350. PubMed ID: 36272360 [TBL] [Abstract][Full Text] [Related]
10. Surveillance of drugs that most frequently induce acute kidney injury: A pharmacovigilance approach. Hosohata K; Inada A; Oyama S; Furushima D; Yamada H; Iwanaga K J Clin Pharm Ther; 2019 Feb; 44(1):49-53. PubMed ID: 30014591 [TBL] [Abstract][Full Text] [Related]
11. Acute Kidney Injury Associated With Remdesivir: A Comprehensive Pharmacovigilance Analysis of COVID-19 Reports in FAERS. Wu B; Luo M; Wu F; He Z; Li Y; Xu T Front Pharmacol; 2022; 13():692828. PubMed ID: 35401177 [TBL] [Abstract][Full Text] [Related]
12. PCSK9 Inhibitors and Neurocognitive Adverse Drug Reactions: Analysis of Individual Case Safety Reports from the Eudravigilance Database. di Mauro G; Zinzi A; Scavone C; Mascolo A; Gaio M; Sportiello L; Ferrajolo C; Rafaniello C; Rossi F; Capuano A Drug Saf; 2021 Mar; 44(3):337-349. PubMed ID: 33351170 [TBL] [Abstract][Full Text] [Related]
13. Risk factors of immune checkpoint inhibitor-associated acute kidney injury: evidence from clinical studies and FDA pharmacovigilance database. Chen P; Zhu J; Xu Y; Huang Q; Su J; Gao Z; Feng M BMC Nephrol; 2023 Apr; 24(1):107. PubMed ID: 37087434 [TBL] [Abstract][Full Text] [Related]
15. A Systematic Review of PCSK9 Inhibitors Alirocumab and Evolocumab. McDonagh M; Peterson K; Holzhammer B; Fazio S J Manag Care Spec Pharm; 2016 Jun; 22(6):641-653q. PubMed ID: 27231792 [TBL] [Abstract][Full Text] [Related]
16. Acute Kidney Injury and Drugs Prescribed for COVID-19 in Diabetes Patients: A Real-World Disproportionality Analysis. Zhou Y; Li J; Wang L; Zhu X; Zhang M; Zheng J Front Pharmacol; 2022; 13():833679. PubMed ID: 35370750 [No Abstract] [Full Text] [Related]
17. Effect of PCSK9 Inhibitor on Contrast-Induced Acute Kidney Injury in Patients with Acute Myocardial Infarction Undergoing Intervention Therapy. Ma Y; Zha L; Zhang Q; Cao L; Zhao R; Ma J; Hou K; Pan Y; Cong H; Li X Cardiol Res Pract; 2022; 2022():1638209. PubMed ID: 36051574 [TBL] [Abstract][Full Text] [Related]
18. Acute kidney injury following SGLT2 inhibitors among diabetic patients: a pharmacovigilance study. Chen G; Li X; Cui Q; Zhou Y; Zhao B; Mei D; Xuemei Int Urol Nephrol; 2022 Nov; 54(11):2949-2957. PubMed ID: 35579781 [TBL] [Abstract][Full Text] [Related]
19. A Pharmacovigilance Study of Adverse Drug Reactions Reported for Cardiovascular Disease Medications Approved Between 2012 and 2017 in the United States Food and Drug Administration Adverse Event Reporting System (FAERS) Database. Patel NM; Stottlemyer BA; Gray MP; Boyce RD; Kane-Gill SL Cardiovasc Drugs Ther; 2022 Apr; 36(2):309-322. PubMed ID: 33599896 [TBL] [Abstract][Full Text] [Related]
20. Comparing Acute Kidney Injury Reports Among Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS). Patek TM; Teng C; Kennedy KE; Alvarez CA; Frei CR Drug Saf; 2020 Jan; 43(1):17-22. PubMed ID: 31691256 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]